![]() |
市場調査レポート
商品コード
1268028
視床下部性肥満 - パイプラインアナリティクス:2023年Hypothalamic Obesity-Pipeline Analytics -2023 |
||||||
|
視床下部性肥満 - パイプラインアナリティクス:2023年 |
出版日: 2023年05月08日
発行: Mellalta Meets LLP
ページ情報: 英文 53 Pages
納期: 即納可能
![]() |
当レポートでは、視床下部性肥満のパイプラインについて調査し、第1相、第2相、第3相のパイプライン動向、市場における競合情勢、法規制動向、パイプラインの薬剤プロファイルなどをまとめています。
The Hypothalamic Obesity report covers the Hypothalamic Obesity market opportunity providing Key Competitive Analysis, 6 Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc.), Licensing and Agreements, Business Agreements, Business Partners as well as Clinical Partner. In addition, our report covers pipeline product analysis by stage of development, competitive landscape by phases, companies, mechanism of action, intervention types. The Hypothalamic Obesity report adds value in terms of describing clinical-stage products concerning their clinical & regulatory timelines as well as in terms of providing the current market opportunity, drivers, and challenges.
Hypothalamic obesity (HyOb) is a complex medical condition that can arise from the development of rare brain tumors or other forms of hypothalamic injury. Among the tumors that can give rise to HyOb, craniopharyngioma is a noteworthy example. Hypothalamic obesity is characterized by an abnormal hypothalamus function, a key aspect of which is its involvement in satiety and food intake regulation. Notably, damage to the ventromedial nucleus of the hypothalamus bilaterally can lead to a syndrome of HyOb that is typified by hyperphagia and obesity, as well as other endocrinal and neurological manifestations.
In this report, Mellalta Meets provides an in-depth analysis of Hypothalamic Obesity pipeline covering Phase III , Phase II & Phase I Pipeline Analysis Overview, Pipeline Products by Stage of Development, Hypothalamic Obesity Competitive Landscape Distinguished by Phase & Route and moleucle type, Clinical Pipeline Products by Company, Hypothalamic Obesity Monotherapy & Combinations Clinical Trials, Pipeline Products by MOA, Hypothalamic Obesity Clinical & Regulatory Timelines, Late-Stage Profiles Comparisons At-a-glance, details of partnerships and business deal values and investments. Currently, there are 6 candidates under evaluation in clinical and preclinical studies. The major key players operating in the market are AstraZeneca, Rhythm Pharmaceuticals, Saniona, Gila Therapeutics, which have robust clinical pipelines of Hypothalamic Obesity candidates.
As per analysis, the development pipeline is full of molecules like small molecules, and peptides.